SAINT (Stroke - Acute Ischemic - NXY Treatment) a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 [Cerovive; AstraZeneca] in acute ischemic stroke

Trial Profile

SAINT (Stroke - Acute Ischemic - NXY Treatment) a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 [Cerovive; AstraZeneca] in acute ischemic stroke

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2010

At a glance

  • Drugs Disufenton (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SAINT-II
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Aug 2007 Results have been published in The New England Journal of Medicine 357: 562-571, No. 6.
    • 26 Oct 2006 Results have been reported.
    • 30 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top